X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (5842) 5842
Newsletter (3728) 3728
Newspaper Article (801) 801
Magazine Article (348) 348
Transcript (195) 195
Book / eBook (19) 19
Conference Proceeding (17) 17
Publication (14) 14
Dissertation (10) 10
Reference (7) 7
Streaming Video (4) 4
Web Resource (4) 4
Book Chapter (3) 3
Report (2) 2
Government Document (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
antilipemic agents (10876) 10876
research (2941) 2941
simvastatin (2572) 2572
cholesterol (2116) 2116
humans (1963) 1963
male (1623) 1623
statins (1517) 1517
analysis (1416) 1416
care and treatment (1373) 1373
medical research (1324) 1324
medicine, experimental (1250) 1250
low density lipoproteins (1173) 1173
female (1162) 1162
pharmaceutical industry (1015) 1015
hypercholesterolemia (1010) 1010
animals (981) 981
middle aged (909) 909
cardiovascular agents (860) 860
atherosclerosis (846) 846
atorvastatin (798) 798
risk factors (790) 790
pharmacology & pharmacy (760) 760
drug therapy (758) 758
drugs (753) 753
health aspects (752) 752
physical fitness (736) 736
universities and colleges (710) 710
rosuvastatin (706) 706
aged (688) 688
pravastatin (667) 667
diabetes (665) 665
coronary heart disease (660) 660
cardiovascular diseases (645) 645
lovastatin (630) 630
prevention (617) 617
cardiac patients (599) 599
cardiovascular (547) 547
lipids (547) 547
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (546) 546
adult (537) 537
hypertension (511) 511
physiological aspects (504) 504
cardiovascular disease (484) 484
clinical trials (480) 480
cancer (471) 471
rats (465) 465
cardiac & cardiovascular systems (453) 453
atorvastatin calcium (436) 436
dosage and administration (432) 432
hydroxymethylglutaryl-coa reductase inhibitors - pharmacology (422) 422
type 2 diabetes (416) 416
inflammation (405) 405
treatment outcome (396) 396
enzymes (395) 395
intellectual property (395) 395
anticholesteremic agents (380) 380
internal medicine (380) 380
mice (362) 362
endothelium (358) 358
simvastatin - pharmacology (354) 354
mortality (344) 344
cardiology (338) 338
apoptosis (334) 334
risk (320) 320
heart attack (300) 300
hydroxymethylglutaryl-coa reductase inhibitors - administration & dosage (299) 299
oxidative stress (297) 297
blood cholesterol (293) 293
c-reactive protein (290) 290
hyperlipidemia (287) 287
medicine (281) 281
stroke (279) 279
disease (276) 276
proteins (276) 276
development and progression (273) 273
studies (272) 272
genetic aspects (271) 271
usage (271) 271
triglycerides (266) 266
cholesterol, ldl - blood (260) 260
expression (260) 260
complications and side effects (254) 254
drug therapy, combination (253) 253
medical colleges (253) 253
simvastatin - therapeutic use (249) 249
methods (247) 247
glucose (244) 244
lipoproteins (244) 244
product development (241) 241
therapy (238) 238
hypercholesterolemia - drug therapy (237) 237
research article (236) 236
anticholesteremic agents - therapeutic use (233) 233
coronary-heart-disease (233) 233
disease models, animal (231) 231
biochemistry & molecular biology (226) 226
metabolism (226) 226
nitric oxide (224) 224
medicine, general & internal (223) 223
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (21) 21
Online Resources - Online (5) 5
Collection Dvlpm't (Acquisitions) - Vendor file (2) 2
Collection Dvlpm't (Acquisitions) - Closed Orders (1) 1
Robarts - Stacks (1) 1
St. Michael's Hospital - Stacks (1) 1
UofT Schools - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (10966) 10966
Spanish (10) 10
French (9) 9
Japanese (7) 7
Portuguese (7) 7
German (4) 4
Turkish (4) 4
Dutch (2) 2
Arabic (1) 1
Chinese (1) 1
Hungarian (1) 1
Korean (1) 1
Serbian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1975, ISBN 9780387073613, Volume 41. Bd., xiii, 488
Book
Arteriosclerosis, thrombosis, and vascular biology, ISSN 1524-4636, 2010, Volume 30, Issue 5, pp. 894 - 899
Several decades ago, fibrates were approved for the treatment of dyslipidemia, whereas thiazolidinediones were screened in animal models to improve glucose... 
Pharmacology | Lipid metabolism | Nuclear receptors | Glucose homeostasis | Atherosclerosis | atherosclerosis | ACID | ETHYL CHLOROPHENOXYISOBUTYRATE | lipid metabolism | ALPHA | ANTI-HYPERLIPIDEMIC AGENTS | RANDOMIZED CONTROLLED-TRIAL | AGONISTS | nuclear receptors | glucose homeostasis | ANTIDIABETIC AGENTS | PPAR-DELTA | pharmacology | PERIPHERAL VASCULAR DISEASE | EXPERIMENTALLY ALTERED CELLS | ACYL-COA OXIDASE | HEMATOLOGY | Hypoglycemic Agents - therapeutic use | Peroxisome Proliferator-Activated Receptors - agonists | Dyslipidemias - drug therapy | Drug Discovery - history | Hypolipidemic Agents - history | History, 21st Century | Thiazolidinediones - history | History, 20th Century | Humans | Treatment Outcome | Diabetes Mellitus, Type 2 - history | Blood Glucose - drug effects | Thiazolidinediones - therapeutic use | Animals | Clofibric Acid - history | Clofibric Acid - therapeutic use | Lipid Metabolism - drug effects | Peroxisome Proliferator-Activated Receptors - history | Dyslipidemias - history | Hypolipidemic Agents - therapeutic use | Hypoglycemic Agents - history | Diabetes Mellitus, Type 2 - drug therapy | Life Sciences | Biochemistry, Molecular Biology | Antilipemic Agents | drug therapy | Dyslipidemias | Blood Glucose | drug effects | Lipid Metabolism | history | Drug Discovery | Hypoglycemic Agents | agonists | Peroxisome Proliferator-Activated Receptors | Clofibric Acid | Diabetes Mellitus, Type 2 | therapeutic use | Thiazolidinediones
Journal Article
Journal Article
PloS one, ISSN 1932-6203, 08/2015, Volume 10, Issue 8, p. e0135634
Aim Unlike rats and mice, hamsters develop hypercholesterolemia, and hypertriglyceridemia when fed a cholesterol-rich diet. Because hyperlipidemia is a... 
CHOLESTEROL ABSORPTION | BODY-WEIGHT | TRANSFER PROTEIN | METABOLIC SYNDROME | GLUCAGON-LIKE PEPTIDE-1 | NEUROMEDIN U | FOOD-INTAKE | GLUCOSE | MULTIDISCIPLINARY SCIENCES | IV INHIBITOR | RECEPTOR | Hypoglycemic Agents - therapeutic use | Cricetinae | Obesity - drug therapy | Cholesterol - blood | Diet, High-Fat - adverse effects | Male | Linagliptin - therapeutic use | Obesity - blood | Anti-Obesity Agents - therapeutic use | Neuropeptides - therapeutic use | Blood Glucose - drug effects | Eating - drug effects | Animals | Anticholesteremic Agents - therapeutic use | Mesocricetus | Peptide YY - therapeutic use | Obesity - etiology | Ezetimibe - therapeutic use | Hypolipidemic Agents - therapeutic use | Peptide Fragments - therapeutic use | Low density lipoproteins | Body weight | Glucose | Hamsters | Cholesterol | Dextrose | Antilipemic agents | Hypercholesterolemia | Diet therapy | Diet | Analysis | Blood lipids | Diabetes | Lipoproteins (low density) | Neurosciences | Peptides | Body fat | Lipids | Metabolic syndrome | Rodents | Supplementation | Lipoproteins (high density) | Sugar | Food | Energy intake | Obesity | Evaluation | Peptidase | Hyperlipidemia | Diabetes mellitus | Dietary supplements | Apolipoproteins | Body weight gain | Glucose tolerance | Weight control | Lipoproteins | Inhibitors | Food intake | Hypertriglyceridemia | Weight reduction | Food preferences | Insulin resistance | Laboratory animals | Endocrinology | Neuromedin
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 2012, Volume 59, Issue 25, pp. 2344 - 2353
Objectives The primary objective of this study was to evaluate the low-density lipoprotein cholesterol (LDL-C)–lowering efficacy of 5 SAR236553/REGN727... 
Cardiovascular | Internal Medicine | statin | low-density lipoprotein cholesterol | safety | apolipoprotein-B | PCSK9 | SAR236553/REGN727 | hypercholesterolemia | CUTANEOUS VASCULITIS | CARDIAC & CARDIOVASCULAR SYSTEMS | METAANALYSIS | CHOLESTEROL | CARDIOVASCULAR OUTCOMES | LOW-DENSITY-LIPOPROTEIN | PREVENTION | REDUCTION | DISEASE | 14 RANDOMIZED-TRIALS | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Proprotein Convertases - antagonists & inhibitors | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Hypercholesterolemia - drug therapy | Time Factors | Pyrroles - administration & dosage | Heptanoic Acids - administration & dosage | Adult | Cholesterol, LDL - blood | Female | Hypercholesterolemia - blood | Double-Blind Method | Proprotein Convertases - metabolism | Treatment Outcome | Anticholesteremic Agents - adverse effects | Drug Synergism | Atorvastatin Calcium | Anticholesteremic Agents - therapeutic use | Antibodies, Monoclonal - administration & dosage | Anticholesteremic Agents - administration & dosage | Aged | Serine Endopeptidases - metabolism | Proprotein Convertase 9 | Care and treatment | Serine | Low density lipoproteins | Antibodies | Thrombin | Lipoprotein A | Cholesterol | Cardiovascular agents | Antilipemic agents | Viral antibodies | Complications and side effects | Hypercholesterolemia | Proteases | Monoclonal antibodies | Universities and colleges | Laboratories | Lipids | Triglycerides | Lipoproteins | Pain | Influenza | Patient safety | Population | Mutation | Clinical medicine | Diabetes | Statins
Journal Article
International journal of antimicrobial agents, ISSN 0924-8579, 2017, Volume 49, Issue 6, pp. 695 - 702
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2017, Volume 376, Issue 16, pp. 1517 - 1526
Journal Article
Journal Article
Journal Article
Journal Article